Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma

• Progression-free survival at 12 weeks (Arm II) [ Designated as safety issue: No ]
• Toxicity [ Designated as safety issue: Yes ]
• Overall survival [ Designated as safety issue: No ]
• Quality of life as measured by EORTC QLQ-C30 and BTM [ Designated as safety issue: No ]
• Cost effectiveness [ Designated as safety issue: No ]

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of chemotherapy is more effective in treating recurrent malignant glioma.

PURPOSE: Randomized phase III trial to compare the effectiveness of temozolomide alone to that of procarbazine, lomustine, and vincristine in treating patients who have recurrent malignant glioma.

OBJECTIVES:

• Compare the efficacy of temozolomide vs procarbazine, lomustine, and vincristine, in terms of overall survival, in patients with recurrent malignant glioma.
• Compare progression-free survival of patients treated with these regimens.
• Compare progression-free survival at 12 weeks in patients treated with two different schedules of temozolomide.
• Compare the overall survival of patients treated with two different schedules of temozolomide.
• Compare toxic effects of two different schedules of temozolomide in these patients.
• Compare quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, controlled, open-label, multicenter study. Patients are randomized to 1 of 2 treatment arms.

• Arm I:Patients are randomized to 1 of 2 treatment schedules:

  • Schedule 1: Patients receive oral temozolomide once daily on days 1-5.
  • Schedule 2:Patients receive oral temozolomide once daily on days 1-21. Treatment on both schedules repeats every 4 weeks for a maximum of 9 courses in the absence of disease progression or unacceptable toxicity.
• Arm II:Patients receive oral lomustine and vincristine IV on day 1 and oral procarbazine on days 1-21. Treatment repeats every 6 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and at 12 and 24 weeks.

Patients are followed every 12 weeks.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 500 patients (250 per treatment arm) will be accrued for this study.

• Drug: lomustine
• Drug: procarbazine hydrochloride
• Drug: temozolomide
• Drug: vincristine sulfate

DISEASE CHARACTERISTICS:

• Histologically confirmed anaplastic astrocytoma, glioblastoma multiforme, or gliosarcoma

  • WHO grade III or IV at diagnosis or relapse
• Must have undergone primary therapy including radiotherapy
• Must be in first recurrence confirmed by CT scan or MRI
• Evaluable disease by CT scan or MRI

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• WHO 0-3

Life expectancy

• At least 1 month

Hematopoietic

• Absolute neutrophil count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3

Hepatic

• Total and direct bilirubin less than 1.5 times upper limit of normal (ULN)
• SGOT or SGPT less than 3 times ULN
• Alkaline phosphatase less than 2 times ULN

Renal

• BUN less than 1.5 times ULN
• Creatinine less than 1.5 times ULN

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No other concurrent serious illness
• Considered fit to receive chemotherapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• No prior chemotherapy for glioma

Endocrine therapy

• Not specified

Radiotherapy

• See Disease Characteristics
• At least 2 months since prior radiotherapy
• No prior radiosurgery, interstitial radiotherapy, or brachytherapy for glioma

Surgery

• Prior debulking surgery for recurrent disease allowed